Hsp90 inhibitor reduces porcine circovirus 2 replication in the porcine monocytic line 3D4/31
Autor: | Ping Jiang, Xuliang Zhang, Jie Liu, Chang Ma, Shifeng Yun |
---|---|
Rok vydání: | 2016 |
Předmět: |
Circovirus
0301 basic medicine Swine animal diseases Virus Replication Antiviral Agents Virus Cell Line Hsp90 inhibitor 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine Virology Heat shock protein Genetics Animals HSP90 Heat-Shock Proteins Circoviridae Infections Molecular Biology Cells Cultured Host factor Swine Diseases Dose-Response Relationship Drug biology virus diseases General Medicine Geldanamycin biology.organism_classification Molecular biology Porcine circovirus 030104 developmental biology chemistry Viral replication 030220 oncology & carcinogenesis |
Zdroj: | Virus Genes. 53:95-99 |
ISSN: | 1572-994X 0920-8569 |
DOI: | 10.1007/s11262-016-1385-z |
Popis: | Porcine circovirus 2 (PCV2) is an important pathogen of swine, which causes porcine circovirus disease and porcine circovirus-associated diseases (PCVD/PCVAD). However, no effective countermeasures exist to combat this virus infection so far. Recently, heat shock protein 90 (Hsp90) was found to be an important host factor for the replication of multiple viruses and the inhibition of Hsp90 showed significant antiviral effects. Inhibition of Hsp90 by treatment of porcine monocytic line 3D4/31 with geldanamycin (GA), a specific inhibitor of Hsp90, caused a 70 % decrease in viral Cap protein expression. Further, individual knockdown targeting Hsp90α or Hsp90β with siRNAs resulted in down to 20-25 % of decrease in viral replication, and inhibited the PCV2 titer by approximately 12- and 15-fold, respectively. In addition, we investigated alteration of several cytokine production in PCV2-infected cells following treatment with GA. Then, we found that GA could decrease IL-1β, IL-6, and IL-12p40 mRNA levels, respectively, by 30, 40, and 40 % in PCV2-infected cells. Our results shed light on the possibility of developing potential therapeutics targeting Hsp90 against PCV2 infection. |
Databáze: | OpenAIRE |
Externí odkaz: |